跳至主要内容
临床试验/NCT00659490
NCT00659490已完成2 期

A Randomised, Double Blind, Placebo-Controlled Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940, in Patients Undergoing Impacted Mandibular Third Molar Extraction

AstraZeneca1 个研究点 分布在 1 个国家目标入组 151 人开始时间: 2008年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
AstraZeneca
入组人数
151
试验地点
1
主要终点
Pain Area Under the Curve 0-8h (AUC0-8h)

研究概览

简要总结

The primary aim of this study is to investigate if AZD1940 can relieve the pain induced by the surgical removal of one lower wisdom-tooth. This will be done by comparing the effect of AZD1940 to placebo ("inactive substance") on pain. A number of patients will instead receive the common painkiller naproxen for comparison purposes. Rescue medication, acetaminophen, will be allowed if a need for additional painkillers would arise. A number of patients will receive Naproxen as control.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Patients scheduled for surgical removal of one partial or complete impacted mandibular third molar.
  • Provision of signed informed consent.
  • Healthy males or non-fertile females.

排除标准

  • History of somatic disease/condition, which may interfere with the objectives of the study, as judged by the investigator.
  • History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in the Diagnostic and Statistical Manual of Mental Disorder, 4th edition.

研究组 & 干预措施

AZD1940

Experimental

AZD1940 800ug given predose

干预措施: AZD1940 (Drug)

Naproxen

Active Comparator

Naproxen 500mg given pre-surgery

干预措施: Naproxen (Drug)

Placebo

Placebo Comparator

Placebo given pre-surgery

干预措施: Placebo (Drug)

结局指标

主要结局

Pain Area Under the Curve 0-8h (AUC0-8h)

时间窗: 0-8 h(from end of surgery to 8 hours post surgery)

Area under the Visual Analogue Scale (VAS, 0-100 mm) time curve 0-8h (from end of surgery). Missing values in the pain-by-time curve was imputated using linear interpolation, last observation carried forward (LOCF) or first observation carried backwards (FOCB) as applicable.

次要结局

  • Pain Area Under the VAS Versus Time Curve 0-4h (AUC0-4h)(0-4h (from end of surgery to 4 hours post surgery))
  • Maximum Pain Based on VAS Scale(From end of surgery to 8h or time first intake of rescue medication (whichever came first))
  • Mean Pain Based on a VAS Scale(From end of surgery to 8h or time to first intake of rescue medication (whichever came first))
  • Pain at Jaw Movement AUC0-8h(0-8h from end of surgery to 8 hours post surgery)
  • Pain at Jaw Movement AUC0-4h(0-4h after end of surgery to 4 hours post surgery)
  • Maximum Pain at Jaw Movement(From end of surgery to 8h or time to first intake of rescue medication (whichever came first))
  • Mean Pain at Jaw Movement(From end of surgery to 8h or time to first intake of rescue medication (whichever came first))
  • Pain at Rescue Medication(At time of first rescue medication taken before 8 hours after end of surgery)
  • Pain at Jaw Movement at Time of First Rescue Medication(At time of first rescue medication (before 8 hours after end on surgery))
  • Time to First Intake of Rescue Medication.(From end of surgery to 8 hours following surgery)
  • Number of Patients Requesting Rescue Medication(End of surgery up to 8hours following surgery)
  • Maximum Deterioration in Visual Analogue Mood Scale (VAMS) Stimulated(Between dosing and 12h post-dose)
  • Maximum Deterioration in VAMS High(Between dosing and 12h post-dose)
  • Maximum Deterioration in VAMS Anxious(Between dosing and 12h post-dose)
  • Maximum Deterioration in VAMS Sedated(Between dosing and 12h post-dose)
  • Maximum Deterioration in VAMS Down(Between dosing and 12h post-dose)
  • Time to Max Deterioration in VAMS Stimulated(Between dosing and 12h post-dose)
  • Time to Max Deterioration in VAMS High(Between dosing and 12h post-dose)
  • Time to Max Deterioration in VAMS Anxious(Between dosing and 12h post-dose)
  • Time to Max Deterioration in VAMS Sedated(Between dosing and 12h post-dose)
  • Time to Max Deterioration in VAMS Down(Between dosing and 12h post-dose)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验